Hypoxia and pancreatic ductal adenocarcinoma

Akio Yamasaki, Kosuke Yanai, Hideya Onishi

研究成果: ジャーナルへの寄稿総説査読

41 被引用数 (Scopus)


Chemotherapy and immunotherapy for pancreatic ductal adenocarcinoma (PDAC) have limited success. One reason for this is thought to be the cancer microenvironment surrounding PDAC. Hypoxia is a feature of the cancer microenvironment. Under hypoxia, different various molecules and signaling pathways are activated compared with normoxia. To develop a new effective therapeutic strategy for PDAC, we need to target these hypoxic conditions to overcome PDAC. To inhibit the malignant phenotype, the cellular changes that occur under hypoxia should be elucidated. Various molecules and signaling that are activated by hypoxia may contribute to the induction of malignant phenotypes of PDAC such as proliferation, invasion, tumorigenesis, chemosensitivity, and autophagy. If we can develop therapeutic approaches to target one of these molecules or signaling pathways, we may proceed to the next therapeutic step of successfully treating refractory PDAC.

ジャーナルCancer Letters
出版ステータス出版済み - 8月 1 2020

!!!All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 癌研究


「Hypoxia and pancreatic ductal adenocarcinoma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。